As one of the first gap cell cycle arrest biomarkers, urinary IGFBP7, multiplied with tissue inhibitor metalloproteinase-2, has been approved by FDA for the acute kidney injury prediction in patients who have acute cardiovascular or respiratory failure (Hasson, Menon & Gist, 2022). The gene discussed is IGFBP7; the disease is acute kidney injury.